Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03807648 · ClinicalTrials.gov registry record

I USE LR in the ED

A clinical trial of Kidney Injury, sponsored by Intermountain Health Care.

Completed
Registry status
200,000
Enrollment target
1
Study location

NCT03807648: Completed study of Kidney Injury, sponsored by Intermountain Health Care.

NCT03807648 is a study of Kidney Injury that has completed, run by Intermountain Health Care. The registered enrollment target is 200,000 participants, above the 307-participant average among 9 other Kidney Injury trials with a reported enrollment target (65047% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03807648, a study of Kidney Injury, has completed, sponsored by Intermountain Health Care.

COMPLETED
Registry status
200,000 participants
Enrollment target
1
Study location

Study Summary

To study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.

Primary Outcome

death from any cause, new renal replacement therapy or persistent renal dysfunction

Conditions Studied

Interventions

  • OTHER Data Inclusion

Study Locations (1)

Utah

  • Intermountain Medical Center - Murray

Trial Details

FieldValue
Enrollment Target 200,000 participants
Start Date 2018-12-20
Est. Completion 2020-01-31
Intermountain Health Care

85 total trials

What the finished NCT03807648 record still lists

NCT03807648 is an observational study that tracks outcomes without assigning an intervention. Its 200,000 participants enrollment target places it among the larger protocols in the corpus, above the 307-participant average among 9 other Kidney Injury trials with a reported enrollment target (65047% higher).

The record links to 1 condition, with Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which Data Inclusion is the first listed.

NCT03807648 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT03807648 about?

NCT03807648 is a clinical study titled "I USE LR in the ED". To study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.

What is the current status of trial NCT03807648?

This trial is currently completed. The enrollment target is 200,000 participants. The study started on 2018-12-20. Estimated completion is 2020-01-31.

What conditions does trial NCT03807648 study?

This clinical trial studies the following conditions: Kidney Injury.

What interventions are being tested in trial NCT03807648?

The interventions under investigation include: Data Inclusion (OTHER).

Who is sponsoring clinical trial NCT03807648?

This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03807648 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03807648's enrollment target sits among peer trials

200,000 1st of 9 higher than 9 of 9 other Kidney Injury trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06090578 · 180,000 participants · NA

    TabCAT Brain Health Assessment in Primary Care

  • NCT06917339 · 156,000 participants

    Retrospective Analyses of TrakStar Database

  • NCT06232551 · 152,000 participants · NA

    Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

  • NCT04735835 · 250,000 participants · NA

    Personalized Responses to Dietary Composition Trial 3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03807648, the US trial registry maintained by the National Library of Medicine. NCT03807648 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.